NCT02644629View on ClinicalTrials.gov

Intra-nasal vs. Intra-venous Ketamine Administration

PHASE4CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

May 31, 2020

Study Completion Date

May 31, 2020

Conditions
Major Depressive Disorder
Interventions
DRUG

Placebo

Saline 0.9%, Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)

DRUG

Ketamine (1st phase)

Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)

DRUG

Ketamine (2st phase)

Patients failing to achieve response (\<50% MADRS score) in the parallal phase, will be offered additional 4 session (twice a week, 2 weeks) of 0.5 mg/kg ketamine over 40 minutes.

Trial Locations (1)

POB 94

Shalvata MHC, Hod HaSharon

All Listed Sponsors
lead

Shalvata Mental Health Center

OTHER

NCT02644629 - Intra-nasal vs. Intra-venous Ketamine Administration | Biotech Hunter | Biotech Hunter